Related Experiment Videos
Magnesium therapy in acute myocardial infarction
P J Visser1, A C Bredero, J B Hoekstra
1Department of Internal Medicine, Diakonessenhuis Utrecht, Netherlands.
Insights
Intravenous magnesium showed potential in reducing mortality in acute myocardial infarction patients during pre-thrombolytic eras. However, current evidence, including trials with thrombolytic agents, does not support its routine use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Magnesium's role in cardiac health has been investigated for its potential anti-arrhythmic and cardioprotective effects.
Purpose of the Study:
- To evaluate the efficacy of intravenous magnesium in managing arrhythmias and reducing mortality in patients with acute myocardial infarction.
- To synthesize findings from multiple clinical trials conducted in different eras of AMI treatment.
Main Methods:
- Systematic review and meta-analysis of nine pre-thrombolytic era trials investigating intravenous magnesium in AMI.
- Analysis of data from large-scale trials like LIMIT-2 and preliminary results from ISIS-4.
Main Results:
- Magnesium demonstrated a mortality reduction in most reviewed studies, with significant benefits in three trials.
- Meta-analyses of smaller studies indicated a 55% mortality reduction.
- The large LIMIT-2 trial showed a significant 24% reduction in mortality.
- The effect on arrhythmias was less conclusive.
- Preliminary ISIS-4 results, combining magnesium with thrombolytics, did not show a clear benefit.
Conclusions:
- While some trials suggest a mortality benefit of magnesium in AMI, particularly in the pre-thrombolytic era, the overall evidence is mixed.
- Current data, especially from trials involving thrombolytic agents, does not support the routine use of magnesium for acute myocardial infarction.
Abstract:
The trials reviewed in this study investigated the effect of intravenous magnesium on arrhythmias and mortality in acute myocardial infarction. Nine trials were carried out in the pre-thrombolytic era. They varied in set-up, number of patients, dose of magnesium, follow-up and the type of arrhythmias analyzed. Magnesium reduced mortality in most studies, but the reduction was significant in only three of them. Two meta-analyses of the smaller studies revealed a 55% reduction in mortality. In the LIMIT-2, in which 2300 patients were enrolled, magnesium reduced mortality significantly by 24%. The effect of magnesium on arrhythmias was less clear. Preliminary results of ISIS-4, in which magnesium among others was administered together with thrombolytic agents, did not provide evidence of benefit in patients with suspected myocardial infarction. At present there are no arguments for the use of magnesium in acute myocardial infarction.